Reprint of "Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells"

被引:7
|
作者
Samper, Katia G. [1 ,2 ]
Marker, Sierra C. [1 ]
Bayon, Pau [2 ]
MacMillan, Samantha N. [1 ]
Keresztes, Ivan [1 ]
Palacios, Oscar [2 ]
Wilson, Justin J. [1 ]
机构
[1] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA
[2] Univ Autonoma Barcelona, Fac Ciencies, Dept Quim, E-08193 Barcelona, Spain
关键词
Cisplatin; Cisplatin resistance; Antitumor drug; Ovarian cancer; Azobenzene; Photodynamic therapy; PHOTOSWITCHABLE ARENE RUTHENIUM; DIMETHYLSULFOXIDE COMPLEXES; PHOTODYNAMIC THERAPY; CLINICAL-USE; PT-195; NMR; DNA; CYTOTOXICITY; LIGANDS; AGENTS; CARBOPLATIN;
D O I
10.1016/j.jinorgbio.2017.07.035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The syntheses of three platinum(II) complexes bearing sulfonamide-((E)-2-(4-methylphenylsulfonamido)-2',6'-difluoroazobenzene, HL1) and hydroxy-azo-2,6-difluorobenzene ((E)-2-((2,6-difluorophenyl)diazenyl)phenol, HL2) bidentate ligands is described. These complexes, [Pt(L1)(DMSO)Cl] (1), [Pt(L2)(DMSO)Cl] (2), and [Pt(L2)2] (3), were characterized by multinuclear NMR spectroscopy, mass spectrometry, and X-ray crystallography. Despite bearing azobenzene functional groups, none of the three complexes undergo photoisomerization. The anticancer activities of these complexes were evaluated in wild-type (A2780) and cisplatin-resistant (A2780CP70) ovarian cancer cells. All three complexes exhibited IC50 values below 10 mu M and displayed similar activity in both A2780 and A2780CP70 cell lines, indicating that they are not cross-resistant with cisplatin. The DNA-binding properties of 1-3 were investigated by circular dichroism spectroscopy and by agarose gel electrophoresis. Both studies suggest that 1 and 2 form monofunctional DNA adducts.
引用
收藏
页码:335 / 343
页数:9
相关论文
共 50 条
  • [21] Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
    Huang, Wei
    Zhou, Quan
    Yuan, Xia
    Ge, Ze-mei
    Ran, Fu-xiang
    Yang, Hua-yu
    Qiang, Guang-liang
    Li, Run-tao
    Cui, Jing-rong
    JOURNAL OF CANCER, 2016, 7 (09): : 1133 - 1141
  • [22] Performance of Ir(III)-Based Anticancer Agents in the Treatment of Cisplatin-Resistant Cancer Cells
    Wang, Meng-Meng
    Li, Hao-Ming
    Deng, Dong-Ping
    Su, Yan
    Su, Zhi
    CHEMMEDCHEM, 2022, 17 (16)
  • [23] Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study
    Gokduman, Kurtulus
    NANOMEDICINE, 2019, 14 (24) : 3177 - 3191
  • [24] Anticancer activity of a trans-platinum(II) complex of 3-aminoflavone to ovarian cancer cells
    Orzechowska, Magdalena
    Fabijanska, Malgorzata
    Ochocki, Justyn
    Malecki, Maciej
    GINEKOLOGIA POLSKA, 2017, 88 (02) : 68 - 74
  • [25] Expression of Ferredoxin1 in cisplatin-resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
    Takahashi, Ryosuke
    Kamizaki, Koki
    Yamanaka, Keitaro
    Terai, Yoshito
    Minami, Yasuhiro
    ONCOLOGY REPORTS, 2023, 49 (06)
  • [26] Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells
    Elias, Maria George
    Aputen, Angelico D.
    Fatima, Shadma
    Mann, Timothy J.
    Karan, Shawan
    Mikhael, Meena
    de Souza, Paul
    Gordon, Christopher P.
    Scott, Kieran F.
    Aldrich-Wright, Janice R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (15)
  • [27] Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer
    Pors, K
    Paniwnyk, Z
    Teesdale-Spittle, P
    Plumb, JA
    Willmore, E
    Austin, CA
    Patterson, LH
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (07) : 607 - 610
  • [28] NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines
    Ghini, Veronica
    Sorbi, Flavia
    Fambrini, Massimiliano
    Magherini, Francesca
    CELLS, 2024, 13 (08)
  • [29] Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells
    Schneiderman, D
    Kim, JM
    Senterman, M
    Tsang, BK
    APOPTOSIS, 1999, 4 (04) : 271 - 282
  • [30] Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
    Amani I. Moraya
    Jennifer L. Ali
    Pranati Samadder
    Lisa Liang
    Ludivine Coudière Morrison
    Tamra E. Werbowetski-Ogilvie
    Makanjuola Ogunsina
    Frank Schweizer
    Gilbert Arthur
    Mark W. Nachtigal
    Journal of Experimental & Clinical Cancer Research, 36